EP Patent

EP3972971A1 — New catecholamine prodrugs for use in the treatment of parkinson's diseases

Assigned to H Lundbeck AS · Expires 2022-03-30 · 4y expired

What this patent protects

The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treat…

USPTO Abstract

The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP3972971A1
Jurisdiction
EP
Classification
—
Expires
2022-03-30
Drug substance claim
No
Drug product claim
No
Assignee
H Lundbeck AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.